Pramine

Nocturnal Enuresis (bedwetting), Bulimia Nervosa, Panic Disorder + 3 more

Treatment

20 Active Studies for Pramine

What is Pramine

Imipramine

The Generic name of this drug

Treatment Summary

Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also block histamine H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively [A6584]. Imipramine has less sedative and anticholinergic effects than the tertiary amine TCAs, amitriptyline and clomipramine. Imipramine may be used to treat depression and nocturnal enuresis in children [FDA Label]. Unlabeled indications include chronic and neuropathic pain (including diabetic neuropathy), panic disorder, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD) [L1349,L1348,A31900,L1351,L1352,L1353,A31904].

Tofranil

is the brand name

Pramine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tofranil

Imipramine

1959

103

When to interrupt dosage

The proposed dosage of Pramine is contingent upon the diagnosed condition. The degree of dosage is dependent on the method of administration outlined in the table beneath.

Condition

Dosage

Administration

Nocturnal Enuresis (bedwetting)

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Bulimia Nervosa

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Neuropathic Pain

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Panic Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Depression

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Attention Deficit Hyperactivity Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Warnings

Pramine Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Myocardial Infarction

Do Not Combine

There are 20 known major drug interactions with Pramine.

Common Pramine Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Imipramine is combined with Aclidinium.

Alfuzosin

Major

Imipramine may increase the hypotensive activities of Alfuzosin.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Imipramine.

Amoxapine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.

Pramine Novel Uses: Which Conditions Have a Clinical Trial Featuring Pramine?

Currently, there are no clinical trials evaluating the utility of Pramine for any particular condition.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Nocturnal Enuresis (bedwetting)

2 Actively Recruiting

Not Applicable

Depression

300 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Bulimia Nervosa

0 Actively Recruiting

Panic Disorder

13 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Patient Q&A Section about pramine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How often can you take Pramin?

"It is best to take Pramin 30 minutes before nausea or vomiting is likely to occur, or 30 minutes before meals. doses of Pramin should be spaced evenly throughout the day, and it is only necessary to take Pramin when required for each occasion of nausea or vomiting."

Answered by AI

Does Pramin make you sleepy?

"Pramin could lead to drowsiness, dizziness, or lightheadedness for some individuals. If you experience any of these symptoms, do not operate any machinery or do anything else that could be harmful."

Answered by AI

What is the drug Paxlovid used for?

"Paxlovid is an oral antiviral pill that is taken at home to help keep high-risk patients from getting so sick that they need to be hospitalized."

Answered by AI

What is Pramine used for?

"Pramine 25 MG Tablet is an antidepressant medicine that is used to treat psychological conditions like obsessive-compulsive disorder, depression, and anxiety disorders like panic attacks. It is also used to treat muscle weakness associated with a sleep disorder called narcolepsy."

Answered by AI

Clinical Trials for Pramine

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. We will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then they will participate in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Have you considered Pramine clinical trials?

We made a collection of clinical trials featuring Pramine, we think they might fit your search criteria.
Go to Trials
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA

The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.

Waitlist Available
Has No Placebo

University of California San Diego

Have you considered Pramine clinical trials?

We made a collection of clinical trials featuring Pramine, we think they might fit your search criteria.
Go to Trials
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL

The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.

Waitlist Available
Has No Placebo

Virtual/ No Physical Facility

Candice S Rasa, LCSW

Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA

The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.

Phase 2
Recruiting

University of California, Los Angeles

Have you considered Pramine clinical trials?

We made a collection of clinical trials featuring Pramine, we think they might fit your search criteria.
Go to Trials